Protein tyrosine phosphatase 1B inhibitory activity of alkaloids from Rhizoma Coptidis and their molecular docking studies

Journal of Ethnopharmacology

Volumn 171, Issue 1, 2015, Pages 28-36

  Choi, Jae Sue ^a   Ali, Md Yousof ^a   Jung, Hyun Ah ^b   Oh, Sang Ho ^c   Choi, Ran Joo ^d   Kim, Eon Ji ^a  

^a Pukyong National University   (South Korea)

^b Chonbuk National University   (South Korea)

^c Korean Bio Information Center (KOBIC)   (South Korea)

^d UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

Alkaloids; Enzyme kinetics; Molecular docking; Protein tyrosine phosphatase 1B; Rhizoma Coptidis

Indexed keywords

ALKALOID; BERBERINE; COPTISINE; EPIBERBERINE; MAGNOFLORINE; PROTEIN TYROSINE PHOSPHATASE 1B; UNCLASSIFIED DRUG; URSOLIC ACID; ANTIDIABETIC AGENT; PEROXYNITROUS ACID; PLANT EXTRACT; PTPN1 PROTEIN, HUMAN; TYROSINE;

ANTIDIABETIC ACTIVITY; ARTICLE; CONTROLLED STUDY; COPTIS CHINENSIS; DRUG ISOLATION; ENZYME INHIBITION; ENZYME KINETICS; IC50; MOLECULAR DOCKING; MOLECULAR INTERACTION; NITRATION; RHIZOME; ANTAGONISTS AND INHIBITORS; CHEMISTRY; COPTIS; ISOLATION AND PURIFICATION; METABOLISM;

COPTIS; COPTIS CHINENSIS;

ALKALOIDS; COPTIS; HYPOGLYCEMIC AGENTS; MOLECULAR DOCKING SIMULATION; PEROXYNITROUS ACID; PLANT EXTRACTS; PROTEIN TYROSINE PHOSPHATASE, NON-RECEPTOR TYPE 1; RHIZOME; TYROSINE;

EID: 84934996262     PISSN: 03788741     EISSN: 18727573     Source Type: Journal    
DOI: 10.1016/j.jep.2015.05.020     Document Type: Article

References (60)

1. Ala, P. J., Gonneville, L., Hillman, M., Becker-Pasha, M., Yue, E. W., Douty, B., Wayland, B., Polam, P., Crawley, M. L., McLaughlin, E., Sparks, R. B., Glass, B., Takvorian, A., Combs, A. P., Burn, T. C., Hollis, G. F., Wynn, R., 2006. Structural insights into the design of nonpeptidic isothiazolidinone-containing inhibitors of proteintyrosine phosphatase 1B. J. Biol. Chem. 281, 38013-38021.
2. Aulak, K. S., Miyagi, M., Yan, L., West, K. A., Massillon, D., Crabb, J. W., Stuehr, D. J., 2001. Proteomic method identifies proteins nitrated in vivo during inflammatory challenge. Proc. Natl. Acad. Sci. USA 98, 12056-12061.
3. Bharatham, K., Bharatham, N., Kwon, Y. J., Lee, K. W., 2008. Molecular dynamics simulation study of PTP1B with allosteric inhibitor and its application in receptor based pharmacophore modeling. J. Comput. Aided Mol. Des. 22, 925-933.
4. Bialy, L., Waldmann, H., 2005. Inhibitors of protein tyrosine phosphatases: nextgeneration drugs? Angew. Chem. 44, 3814-3839.
5. Bustanji, Y., Al-Masri, I. M., Qasem, A., Al-Bakri, A. G., Taha, M. O., 2009. In silico screening for non-nucleoside HIV-1 reverse transcriptase inhibitors using physicochemical filters and high-throughput docking followed by in vitro evaluation. Chem. Biol. Drug Des. 74, 258-265.
6. Bustanji, Y., Taha, M. O., Yousef, A. M., Al-Bakri, A. G., 2006. Berberine potently inhibits protein tyrosine phosphatase 1B: investigation by docking simulation and experimental validation. J. Enzyme Inhib. Med. Chem. 21, 163-171.
7. Ceriello, A., Mercuri, F., Quagliaro, L., Assaloni, R., Motz, E., Tonutti, L., Tabaga, C., 2001. Detection of nitrotyrosine in the diabetic plasma: evidence of oxidative stress. Diabetologia 44, 834-838.
8. Chen, C., Zhang, Y., Huang, C., 2010. Berberine inhibits PTP1B activity and mimics insulin action. Biochem. Biophys. Res. Commun. 397, 543-547.
9. Chen, Q. B., Xin, X. L., Yang, Y., Lee, S. S., Aisa, A. H., 2014. Highly conjugated norditerpenoid and pyrroloquinoline alkaloids with potent PTP1B inhibitory activity from Nigella glandulifera. J. Nat. Prod. 77, 807-812.
10. Choi, J. S., Kim, J. H., Ali, M. Y., Byung, S. M., Kim, D. G., Jung, H. A., 2014. Coptis chinensis alkaloids exert anti-adipogenic activity on 3T3-L1 adipocytes by downregulating C/EBP-α and PPAR-γ. Fitoterapia 98, 199-208.
11. Combs, A. P., 2010. Recent advances in the discovery of competitive protein tyrosine phosphatase 1B inhibitors for the treatment of diabetes, obesity, and cancer. J. Med. Chem. 53, 2333-2344.
12. Cornish-Bowden, A., 1974. A simple graphical method for determining the inhibition constants of mixed, uncompetitive and non-competitive inhibitors. Biochem. J. 137, 143-144.
13. Cui, L., Na, M., Oh, H., Bae, E. Y., Jeong, D. G., Ryu, S. E., Kim, S., Kim, B. Y., Oh, W. K., Ahn, J. S., 2006. Protein tyrosine phosphatase 1B inhibitors from Morus root bark. Bioorg. Med. Chem. Lett. 16, 1426-1429.
14. Dixon, M., 1953. The determination of enzyme inhibitor constants. Biochem. J. 55, 170-171.
15. Doggrell, S. A., 2005. Berberine-a novel approach to cholesterol lowering. Expert Opin. Investig. Drugs 14, 683-685.
16. Duez, H., Cariou, B., Staels, B., 2012. DPP-4 inhibitors in the treatment of type 2 diabetes. Biochem. Pharmacol. 83, 823-832.
17. Elchebly, M., Payette, P., Michaliszyn, E., Cromlish, W., Collins, S., Loy, A. L., Normandin, D., Cheng, A., Himms-Hagen, J., Chan, C. C., Ramachandran, C., Gresser, M. J., Tremblay, M. L., Kennedy, B. P., 1999. Increased insulin sensitivity and obesity resistance in mice lacking the protein tyrosine phosphatase-1B gene. Science 283, 1544-1548.
18. González-Rodríguez, A., Más-Gutierrez, J. A., Mirasierra, M., Fernandez-Pérez, A., Lee, Y. J., Ko, H. J., Kim, J. K., Romanos, E., Carrascosa, J. M., Ros, M., Vallejo, M., Rondinone, C. M., Valverde, A. M., 2012. Essential role of protein tyrosine phosphatase 1B in obesity-induced inflammation and peripheral insulin resistance during aging. Aging Cell 11, 284-296.
19. Grycová, L., Dostál, J., Marek, R., 2007. Quaternary protoberberine alkaloids. Phytochemistry 68, 150-175.
20. Hsieh, Y. S., Kuo, W. H., Lin, T. W., Chang, H. R., Lin, T. H., Chen, P. N., Chu, S. C., 2007. Protective effects of berberine against low-density lipoprotein (LDL) oxidation and oxidized LDL-induced cytotoxicity on endothelial cells. J. Agric. Food Chem. 55, 10437-10445.
21. Huang, C., Zhang, Y., Gong, Z., Sheng, X., Li, Z., Zhang, W., Qin, Y., 2006. Berberine inhibits 3T3-L1 adipocyte differentiation through the PPARγ pathway. Biochem. Biophys. Res. Commun. 348, 571-578.
22. Huang, K. C., 1999. The Pharmacology of Chinese Herbs. CRC Press Inc., Boca Raton: FL, pp. 381-382.
23. Hung, T. M., Lee, J. P., Min, B. S., Choi, J. S., Na, M., Zhang, X., Ngoc, T. M., Lee, I., Bae, K., 2007. Magnoflorine from Coptidis Rhizoma protects high density lipoprotein during oxidant stress. Biol. Pharm. Bull. 30, 1157-1160.
24. International Diabetes Federation. 2013. IDF Diabetes Atlas, 6th ed. Brussels, Belgium: International Diabetes Federation, 〈http://www.idf.org/diabetesatla〉.
25. Inzucchi, S. E., 2002. Oral antihperglycemic therapy for type 2 diabetes. J. Am. Med. Assoc. 287, 360-372.
26. Ischiropoulos, H., 1998. Biological tyrosine nitration: a pathophysiological function of nitric oxide and reactive oxygen species. Arch. Biochem. Biophys. 356, 1-11.
27. Jiang, X. F., Wang, L. J., Li, X. G., Zhao, Z. Q., Zhu, J. Y., 2011. Isolation of jatrorrhizine and epiberberine in Coptis chinensis and their in vitro hypoglycemic effect. Guizhou Agric. Sci. 39, 44-46.
28. Johnson, T. O., Ermolieff, J., Jirousek, M. R., 2002. Protein tyrosine phosphatase 1B inhibitors for diabetes. Nat. Rev. Drug Discov. 1, 696-709.
29. Jung, H. A., Cho, Y. S., Oh, S. H., Lee, S., Min, B. S., Moon, K. H., Choi, J. S., 2013. Kinetics and molecular docking studies of pimarane-type diterpenes as protein tyrosine phosphatase (PTP1B) inhibitors from Aralia continentalis roots. Arch. Pharm. Res. 36, 360-372.
30. Jung, H. A., Min, B. S., Yokazawa, T., Lee, J. H., Kim, Y. S., Choi, J. S., 2009. Anti-alzheimer and antioxidant activities of Coptidis Rhizoma Alkaloids. Biol. Pharm. Bull. 32, 1433-1438.
31. Jung, H. A., Yoon, N. Y., Bae, H. J., Min, B. S., Choi, J. S., 2008. Inhibitory activities of the alkaloids from Coptidis Rhizoma against aldose reductase. Arch. Pharm. Res. 31, 1405-1412.
32. Kamerlin, S. C., Rucker, R., Boresch, S., 2007. A molecular dynamics study of WPD-loop flexibility in PTP1B. Biochem. Biophys. Res. Commun. 356, 1011-1016.
33. Kasibhatla, B., Wos, J., Peters, K. G., 2007. Targeting protein tyrosine phosphatase to enhance insulin action for the potential treatment of diabetes. Curr. Opin. Investig. Drugs 8, 805-813.
34. Ko, W. H., Yao, X. Q., Lau, C. W., Law, W. I., Chen, Z. Y., Kwok, W., Ho, K., Huang, Y., 2000. Vasorelaxant and antiproliferative effects of berberine. Eur. J. Pharmacol. 399, 187-196.
35. Koren, S., Fantus, I. G., 2007. Inhibition of the protein tyrosine phosphatase PTP1 B: potential therapy for obesity, insulin resistance and type-2 diabetes mellitus. Best Pract. Res. Clin. Endocrinol. Metab. 21, 621-640.
36. Kuo, C. L., Chi, C. W., Liu, T. Y., 2004. The anti-inflammatory potential of berberine in vitro and in vivo. Cancer Lett. 203, 127-137.
37. Lee, H. Y., Kim, C. W., 1997. Studies on the constituents of Berberis amurensis Ruprecht. Korean J. Pharmacogn. 28, 257-263.
38. Leng, S. H., Lu, F. E., Xu, L. J., 2004. Therapeutic effects of berberine in impaired glucose tolerance rats and its influence on insulin secretion. Acta. Pharmacol. Sin. 25, 496-502.
39. 1H NMR and its application for quality control of commercial prescriptions. J. Pharm. Biomed. Anal. 49, 1272-1276.
40. Lineweaver, H., Burk, D., 1934. The determination of enzyme dissociation constants. J. Am. Chem. Soc. 56, 658-666.
41. Morris, G. M., Huey, R., Lindstrom, W., Sanner, M. F., Belew, R. K., Goodsell, D. S., Olson, A. J., 2009. AutoDock4 and AutoDockTools4: automated docking with selective receptor flexibility. J. Comput. Chem. 30, 2785-2791.
42. Patel, M. B., Mishra, S., 2011. Hypoglycemic activity of alkaloidal fraction of Tinospora cordifolia. Phytomedicine 18, 1045-1052.
43. Popov, D., 2011. Novel protein tyrosine phosphatase 1B inhibitors: interaction requirements for improved intracellular efficacy in type 2 diabetes mellitus and obesity control. Biochem. Biophys. Res. Commun. 410, 377-381.
44. Rackova, L., Majekova, M., Kostalova, D., Stefek, M., 2004. Antiradical and antioxidant activities of alkaloids isolated from Mahonia aquifolium. Structural aspects. Bioorg. Med. Chem. 12, 4709-4715.
45. Rader, D. J., 2007. Effect of insulin resistance, dyslipidemia, and intra-abdominal adiposity on the development of cardiovascular disease and diabetes mellitus. Am. J. Med. 120, S12-S18.
46. Sasaki, T., Li, W., Higai, K., Koike, K., 2015. Canthinone alkaloids are novel protein tyrosine phosphatase 1B inhibitors. Bioorg. Med. Chem. Lett. 25, 1979-1981.
47. Schinella, G. R., Tournier, H. A., Prieto, J. M., Mordujovich De Buschiazzo, P., Ríos, J. L., 2002. Antioxidant activity of anti-inflammatory plant extracts. Life Sci. 70, 1023-1033.
48. Sun, J., Ma, J. S., Jin, J., Wang, H. S., Wen, Q. H., Zhang, H. G., Zhou, Q. L., 2006. Qualitative and quantitative determination of the main components of huanglianjiedu decoction by HPLC-UV/MS. Yao Xue Xue Bao 41, 380-384.
49. Tang, L. Q., Wei, W., Chen, L. M., Liu, S., 2006. Effects of berberine on diabetes induced by alloxan and a high-fat/high-cholesterol diet in rats. J. Ethnopharmacol. 108, 109-115.
50. Tonks, N. K., Neel, B. G., 2001. Combinatorial control of the specificity of protein tyrosine phosphatases. Curr. Opin. Cell. Biol. 13, 182-195.
51. Tse, W. P., Che, C. T., Liu, K., Lin, Z. X., 2006. Evaluation of the anti-proliferative properties of selected psoriasis-treating Chinese medicines on cultured HaCaT cells. J. Ethnopharmacol. 108, 133-141.
52. Turkoski, B. B., 2006. Diabetes and diabetes medications. Orthop. Nurs. 25, 227-231.
53. Wiesmann, C., Barr, K. J., Kung, J., Zhu, J., Erlanson, D. A., Shen, W., Fahr, B. J., Zhong, M., Taylor, L., Randall, M., McDowell, R. S., Hansen, S. K., 2004. Allosteric inhibition of protein tyrosine phosphatase 1B. Nat. Struct. Mol. Biol. 11, 730-737.
54. Wu, X., Hardy, V. E., Joseph, J. I., Jabbour, S., Mahadev, K., Zhu, L., Goldstein, B. J., 2003. Protein-tyrosine phosphatase activity in human adipocytes is strongly correlated with insulin-stimulated glucose uptake and is a target of insulin-induced oxidative inhibition. Metabolism 52, 705-712.
55. Xu, H.-Y., Zhang, T.-J., Zhu, X.-Y., Li, Y.-B., 2009. Recent advance on chemical compositions and pharmacodynamic and pharmacokinetic studies of Rhizoma Coptidis. Asian J. Pharmacodyn. Pharmacokinet. 9, 11-25.
56. Yin, J., Chen, M., Tang, J., 2004. Effects of berberine on glucose and lipid metabolism in animal experiment. Chin. J. Diabetes 12, 215-218.
57. Yokozawa, T., Satoh, A., Cho, E. J., Kashiwada, Y., Ikeshiro, Y., 2005. Protective role of Coptidis Rhizoma alkaloids against peroxynitrite-induced damage to renal tubular epithelial cells. J. Pharm. Pharmacol. 57, 367-374.
58. Yuan, L., Tu, D., Ye, X., Wu, J., 2006. Hypoglycemic and hypocholesterolemic effects of Coptis chinensis Franch inflorescence. Plant Foods Hum. Nutr. 61, 139-144.
59. Zhou, H., Jiang, T., Wang, Z., Ren, S., Zhao, X., Wu, W., Jiang, L., Liu, Z., Teng, L., 2014. Screening for potential-α-glucosidase inhibitors in Coptis chinensis Franch extract using ultrafiltration LC-ESI-MSn. Pak. J. Pharm. Sci. 27, 2007-2012.
60. Zinker, B. A., Rondinone, C. M., Trevillyan, J. M., Gum, R. J., Clampit, J. E., Waring, J. F., Xie, N., Wilcox, D., Jacobson, P., Frost, L., Kroeger, P. E., Reilly, R. M., Koterski, S., Opgenorth, T. J., Ulrich, R. G., Crosby, S., Butler, M., Murray, S. F., McKay, R. A., Bhanot, S., Monia, B. P., Jirousek, M. R., 2002. PTP1B antisense oligonucleotide lowers PTP1B protein, normalizes blood glucose, and improves insulin sensitivity in diabetic mice. Proc. Natl. Acad. Sci. USA 99, 11357-11362.